![]() Edge Therapeutics Edge Therapeutics, a clinical-stage biotechnology company, transforms FDA-approved drugs into therapies that address unmet acute neurological conditions. | Biogen Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. | ![]() Cadila Pharmaceuticals Cadila Pharmaceuticals is a company that develops and manufactures medicines for patients. | ||
Founding Date | Founding Date 2009 | Founding Date 1929 | Founding Date 1978 | Founding Date 1951 |
Type | Type Subsidiary | Type Public | Type Public | Type Private |
Tags | ||||
Locations | Locations Berkeley Heights, US HQ | Locations Boulogne-Billancourt, FR HQ Algiers, DZ South Yarra, AU Wien, AT Merelbeke, BE São Paulo, BR Mississauga, CA see more | Locations Cambridge, US HQ Vicente López, AR Macquarie Park, AU Wien, AT Machelen, BE São Paul, BR Toronto, CA see more | |
Employees | Employees 10 | Employees 5,358 | Employees 7,605 | Employees 8,5201% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 10.2 b | Valuation ($) 26.7 b | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) €3.7b (FY, 2025) | Revenue (est.) $9.9b (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods €659.1m (FY, 2025) | Cost of goods $2.4b (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit €3.3b (FY, 2025) | Gross profit $7.5b (FY, 2025) | Gross profit N/A |
Net income | Net income ($16.9m) (FY, 2021) | Net income €445.1m (FY, 2025) | Net income $1.3b (FY, 2025) | Net income N/A |
Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases.
View company
Cadila Pharmaceuticals is a company that develops and manufactures medicines for patients.
View company